Precirix NV successfully closed an EUR 80 million Series B financing round, led by INKEF Capital, Jeito Capital, and Forbion, to advance its innovative radiopharmaceutical CAM-H2 for oncology applications.

Target Company Overview

Precirix NV is a clinical-stage biotechnology firm based in Brussels, Belgium, focused on developing precision radiopharmaceuticals for oncology applications. Founded in 2014 as a spin-off from the VUB, Precirix aims to enhance and prolong the lives of cancer patients by creating innovative therapies utilizing camelid single-domain antibodies coupled with radioisotopes. The company is progressing its pipeline, which includes one product candidate in a Phase I/II clinical trial and two more in advanced preclinical stages.

The company’s lead product candidate, CAM-H2, is currently undergoing a Phase I/II trial targeting HER2-positive metastatic breast and gastric cancer. This trial notably includes patients with brain metastases, a demographic that urgently requires new effective treatment options. Preliminary imaging results are promising, indicating CAM-H2's potential to meet this critical medical need, as the company has now entered the second cohort of the dose-escalation phase following favorable initial safety outcomes.

Industry Overview in Belgium

Belgium is home to a robust and rapidly evolving biotechnology sector, recognized globally for its innovation and specialized research capabilities. The country hosts a multitude of biotech firms and research institutions, contributing si